X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand

Content Team by Content Team
11th September 2020
in News
Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand

National Science and Technology Development Agency Thailand (NSTDA) is implementing the Government’s Thailand 4.0 initiative to promote strategic biotechnology growth at the country’s Eastern Economic Corridor of Innovation (EECi). One part of this new BIOPOLIS complex is the GMP Biorefinery Pilot Plant at EECi, for which German engineering company Glatt Ingenieurtechnik was selected to provide the engineering services. The contract between NSTDA and Glatt comprises the Conceptual and Basic Design phases for the GMP Biorefinery.

The main objective of the GMP Biorefinery Pilot Plant at EECi is to provide a “non-proprietary (generic) equipment” platform for private and public organizations, as well as local and international universities to scale-up and validate their laboratory prototypes and perform techno-economic feasibility studies before investing in specific production lines.

The Biorefinery platform will be designed in such a way that allows users to reconfigure the unit operation arrangement (“LEGO® box” concept) and adjust the operating parameters to extreme values to optimize the process conditions (flexible process window for optimization) and customize or scale-up the equipment. Glatt Ingenieurtechnik in Germany will lead the engineering project and design the biotech process plant.

Eastern Economic Corridor of Innovation (EECi) aims to advance and transform existing industries, both within the EEC and in other parts of the Thailand, through innovative research and development and advanced laboratory scale technology development to actual industrial application. Innovative Agriculture and Biorefinery are among the target industries of EECi. Thailand has developed a basic infrastructure to support the growth of the Biorefinery industry. Thailand’s Government has approved the investment policy infrastructure at EECi as a central facility to advance targeted Biorefinery technologies to higher Technology Readiness Level (TRL).

National Science and Technology Development Agency Thailand (NSTDA) is a government agency established to promote the development of science and technology in Thailand. NSTDA has multiple cooperations worldwide with research institutes, innovate industry, university and many companies. NSTDA was established in December 1991 as an autonomous Government agency under the National Science and Technology Development Act 1991. NSTDA is affiliated to the Ministry of Higher Education, Science, Research and Innovation, with the Minister serving as the chairman of NSTDA Governing Board. NSTDA is entrusted with an important task to accelerate science, technology and innovation development in Thailand to respond to the need of the industry and enhance the country’s competitiveness in the global economy, and as a result, making contribution to national economic and social development. NSTDA’s mission is to perform and support Research and Development, Design and Engineering, Technology Transfer, Science and Technology Human Resource Development and Infrastructure Development. This mission is implemented through working with partners from academic, government, private, and non-government sectors, both domestically and internationally.

Glatt Ingenieurtechnik GmbH plans and carries out international projects from the enlargement or modernization of existing production facilities to the construction of whole new factories. In doing so, the company combines professional engineering with sound technical know-how derived from patented process technologies it has developed itself, such as Glatt powder synthesis and fluidized and spouted bed methods for granulation and coating processes. The focus of the projects is on processes in the field of particle design and particle engineering for the development, optimization, functionalization and production of powder and bulk goods such as granulates and pellets for food, feed, chemicals and fine chemicals and processes for the manufacture of biotechnological and chemical active ingredients for sterile and non-sterile dosage forms of drugs.

Within the competence area of Process & Plant Engineering the company provides long year competences in biotechnological projects as well as in chemical synthesis engineering and has wide project experience in Asia, including Thailand, India, China, Vietnam, Bangladesh and further countries.

Previous Post

World's Largest Virtual Pharma Expo Agenda Unveiled:

Next Post

New Concept Allows Physical Partnering Event

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
New Concept Allows Physical Partnering Event

New Concept Allows Physical Partnering Event

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In